{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:31:35Z","timestamp":1794537095138,"version":"4.9.1"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The role of Zona pellucida glycoprotein 3 (ZP3) is unclear in pancreatic\nadenocarcinoma (PAAD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to explore the role of ZP3 in PAAD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comparative analysis of ZP3 gene expression was performed to discern differences between\nvarious types of cancer and PAAD, leveraging data sourced from The Cancer Genome Atlas\n(TCGA). This study aimed to assess the role of ZP3 as a potential diagnostic marker for\nPAAD. The relationship between ZP3 levels and clinical characteristics, as well as patient outcomes,\nwas scrutinized. Additionally, genomic enrichment analysis was carried out to uncover the\nunderlying regulatory mechanisms associated with ZP3. The study further delved into the association\nof ZP3 with immune system interactions, checkpoint gene expression, Tumor Mutational Burden\n(TMB), microsatellite instability (MSI), and tumor stemness index (mRNAsi). The aberrant\nexpression patterns of ZP3 in PAAD cell cultures were confirmed through the application of quantitative\nreverse transcription PCR (qRT-PCR) techniques.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>ZP3 exhibited aberrant expression in both pan-cancer and PAAD. A significant correlation\nwas observed between increased levels of ZP3 expression in PAAD patients and histologic\ngrade (p = 0.026). Elevated ZP3 expression in PAAD was found to be significantly associated\nwith poorer overall survival (p = 0.003), progression-free survival (p = 0.012), and disease-specific\nsurvival (p = 0.002). In PAAD, the level of ZP3 gene expression was statistically significant (p\n&lt; 0.001) and recognized as a key determinant of patient prognosis. ZP3 exhibited associations\nwith various biological pathways, including primary immunodeficiency, oxidative phosphorylation,\nand other pathways. ZP3 expression demonstrated correlations with immune infiltration, immune\ncheckpoint genes, TMB, MSI, and mRNAsi in PAAD. Moreover, a pronounced negative\ncorrelation was detected between ZP3 expression levels and the therapeutic effectiveness of various\nmedications, including selumetinib, bleomycin, FH535, docetaxel, and tanespimycin, within\nthe context of PAAD. Elevated levels of ZP3 were consistently observed in cell line models of\nPAAD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>ZP3 has the potential to serve as a prognostic biomarker and therapeutic target for patients\nwith PAAD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298665350171241204153202","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T07:59:04Z","timestamp":1736495944000},"page":"124-138","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["ZP3 Expression in Pancreatic Adenocarcinoma: Its Implications for the Prognosis and Therapy"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-7318","authenticated-orcid":true,"given":"Guizhen","family":"Lyu","sequence":"first","affiliation":[{"name":"Scientific Research Center, Dongguan Labway Medical Testing Laboratory Co., Ltd., Dongguan, 523429, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5227-9643","authenticated-orcid":true,"given":"Dongbing","family":"Li","sequence":"additional","affiliation":[{"name":"Scientific\nResearch Center, Beijing ChosenMed Clinical Laboratory Co., Ltd. Beijing, 100176, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"McGuigan A.","year":"2018","unstructured":"McGuigan A.; Kelly P.; Turkington R.C.; Jones C.; Coleman H.G.; McCain R.S.; Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol  2018,24(43),4846-4861","journal-title":"World J Gastroenterol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"Mizrahi J.D.","year":"2020","unstructured":"Mizrahi J.D.; Surana R.; Valle J.W.; Shroff R.T.; Pancreatic cancer. Lancet  2020,395(10242),2008-2020","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"Hessmann E.","year":"2020","unstructured":"Hessmann E.; Buchholz S.M.; Demir I.E.; Singh S.K.; Gress T.M.; Ellenrieder V.; Neesse A.; Microenvironmental determinants of pancreatic cancer. Physiol Rev  2020,100(4),1707-1751","journal-title":"Physiol Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","volume":"13","author":"Qian Y.","year":"2020","unstructured":"Qian Y.; Gong Y.; Fan Z.; Luo G.; Huang Q.; Deng S.; Cheng H.; Jin K.; Ni Q.; Yu X.; Liu C.; Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol  2020,13(1),130","journal-title":"J Hematol Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1095\/biolreprod.108.074716","volume":"81","author":"Bansal P.","year":"2009","unstructured":"Bansal P.; Chakrabarti K.; Gupta S.K.; Functional activity of human ZP3 primary sperm receptor resides toward its C-terminus. Biol Reprod  2009,81(1),7-15","journal-title":"Biol Reprod"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cell.2010.10.013","volume":"143","author":"Wassarman P.M.","year":"2010","unstructured":"Wassarman P.M.; Litscher E.S.; Egg\u2019s ZP3 structure speaks volumes. Cell  2010,143(3),337-338","journal-title":"Cell"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/humrep\/deh301","volume":"19","author":"Lefi\u00e8vre L.","year":"2004","unstructured":"Lefi\u00e8vre L.; Conner S.J.; Salpekar A.; Olufowobi O.; Ashton P.; Pavlovic B.; Lenton W.; Afnan M.; Brewis I.A.; Monk M.; Hughes D.C.; Barratt C.L.; Four zona pellucida glycoproteins are expressed in the human. Hum Reprod  2004,19(7),1580-1586","journal-title":"Hum Reprod"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1095\/biolreprod.108.069344","volume":"79","author":"Chiu P.C.N.","year":"2008","unstructured":"Chiu P.C.N.; Wong B.S.T.; Chung M.K.; Lam K.K.W.; Pang R.T.K.; Lee K.F.; Sumitro S.B.; Gupta S.K.; Yeung W.S.B.; Effects of native human zona pellucida glycoproteins 3 and 4 on acrosome reaction and zona pellucida binding of human spermatozoa. Biol Reprod  2008,79(5),869-877","journal-title":"Biol Reprod"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/humrep\/dem373","volume":"23","author":"Gook D.A.","year":"2007","unstructured":"Gook D.A.; Edgar D.H.; Borg J.; Martic M.; Detection of zona pellucida proteins during human folliculogenesis. Hum Reprod  2007,23(2),394-402","journal-title":"Hum Reprod"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2174\/1386207325666221010112601","volume":"26","author":"Bi Y.","year":"2023","unstructured":"Bi Y.; Jin S.; Tang G.; Pan D.; Song X.; Zhu X.; Tan S.; Prognostic significance of ZP3 in hepatocellular carcinoma. Comb Chem High Throughput Screen  2023,26(9),1729-1736","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1096\/fj.11-192468","volume":"26","author":"Rahman N.A.","year":"2012","unstructured":"Rahman N.A.; Bennink H.J.T.C.; Chrusciel M.; Sharp V.; Zimmerman Y.; Dina R.; Li X.; Ellonen A.; Rivero-M\u00fcller A.; Dilworth S.; Ghaem-Maghami S.; Vainio O.; Huhtaniemi I.; A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J  2012,26(1),324-333","journal-title":"FASEB J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1038\/s41598-021-86888-7","volume":"11","author":"Ahluwalia P.","year":"2021","unstructured":"Ahluwalia P.; Ahluwalia M.; Mondal A.K.; Sahajpal N.; Kota V.; Rojiani M.V.; Rojiani A.M.; Kolhe R.; Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma. Sci Rep  2021,11(1),7561","journal-title":"Sci Rep"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.3390\/cancers14246220","volume":"14","author":"Yang D.","year":"2022","unstructured":"Yang D.; Liu M.; Jiang J.; Luo Y.; Wang Y.; Chen H.; Li D.; Wang D.; Yang Z.; Chen H.; Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma. Cancers (Basel)  2022,14(24),6220","journal-title":"Cancers (Basel)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"15330338231154091","DOI":"10.1177\/15330338231154091","volume":"22","author":"Han Q.","year":"2023","unstructured":"Han Q.; Cui Z.; Wang Q.; Pang F.; Li D.; Wang D.; Upregulation of OTX2-AS1 is associated with immune infiltration and predicts prognosis of gastric cancer. Technol Cancer Res Treat  2023,22,15330338231154091","journal-title":"Technol Cancer Res Treat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/PGPM.S384901","volume":"15","author":"Liang W.","year":"2022","unstructured":"Liang W.; Lu Y.; Pan X.; Zeng Y.; Zheng W.; Li Y.; Nie Y.; Li D.; Wang D.; Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm Genomics Pers Med  2022,15,985-998","journal-title":"Pharm Genomics Pers Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/CAD.0000000000001341","volume":"34","author":"Wang J.","year":"2023","unstructured":"Wang J.; Dai W.; Zhang M.; GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway. Anticancer Drugs  2023,34(1),57-72","journal-title":"Anticancer Drugs"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.2147\/IJGM.S335821","volume":"14","author":"Pan H.","year":"2021","unstructured":"Pan H.; Liu Q.; Zhang F.; Wang X.; Wang S.; Shi X.; High STK40 expression as an independent prognostic biomarker and correlated with immune infiltrates in low-grade gliomas. Int J Gen Med  2021,14,6389-6400","journal-title":"Int J Gen Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.2147\/IJGM.S340683","volume":"14","author":"Lin Z.","year":"2021","unstructured":"Lin Z.; Huang W.; Yi Y.; Li D.; Xie Z.; Li Z.; Ye M.; LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma. Int J Gen Med  2021,14,8541-8555","journal-title":"Int J Gen Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1179120","DOI":"10.3389\/fonc.2023.1179120","volume":"13","author":"Rui S.","year":"2023","unstructured":"Rui S.; Wang D.; Huang Y.; Xu J.; Zhou H.; Zhang H.; Prognostic value of SLC4A4 and its correlation with the microsatellite instability in colorectal cancer. Front Oncol  2023,13,1179120","journal-title":"Front Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.2174\/0113816128254621231017062923","volume":"29","author":"Huang H.","year":"2023","unstructured":"Huang H.; Xu Q.; Zhang Y.; Zhou Y.; Ma K.; Luo Y.; miR-628-5p is a potential novel prognosis biomarker, associated with immune infiltration in bladder urothelial carcinoma. Curr Pharm Des  2023,29(31),2477-2488","journal-title":"Curr Pharm Des"},{"key":"ref=21","first-page":"e934522","volume":"27","author":"Yi W.","year":"2021","unstructured":"Yi W.; Shen H.; Sun D.; Xu Y.; Feng Y.; Li D.; Wang C.; Low expression of long noncoding RNA SLC26A4 antisense RNA 1 is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer. Med Sci Monit  2021,27,e934522","journal-title":"Med Sci Monit"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.2147\/IJGM.S326402","volume":"14","author":"Chen J.","year":"2021","unstructured":"Chen J.; Tang H.; Li T.; Jiang K.; Zhong H.; Wu Y.; He J.; Li D.; Li M.; Cai X.; Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer. Int J Gen Med  2021,14,3951-3960","journal-title":"Int J Gen Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/0109298665255704230920063254","volume":"30","author":"Ren Z.","year":"2023","unstructured":"Ren Z.; Zhang X.; Han J.; Expression and prognostic significance of ferroptosis-related proteins SLC7A11 and GPX4 in renal cell carcinoma. Protein Pept Lett  2023,30(10),868-876","journal-title":"Protein Pept Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2174\/0929866530666230314160234","volume":"30","author":"Ren S.","year":"2023","unstructured":"Ren S.; Chen M.; Chen Y.; Ding K.; NRSN2 is a prognostic biomarker in gastric cancer and facilitates the growth and migration of gastric cancer cells. Protein Pept Lett  2023,30(5),427-438","journal-title":"Protein Pept Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/0109298665314658240712051206","volume":"31","author":"Wang M.","year":"2024","unstructured":"Wang M.; Li W.; Han G.; Bai X.; Xie J.; MicroRNA-605-3p inhibited the growth and chemoresistance of osteosarcoma cells via negatively modulating RAF1. Protein Pept Lett  2024,31(7),559-568","journal-title":"Protein Pept Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e0290031","DOI":"10.1371\/journal.pone.0290031","volume":"18","author":"Chen B.","year":"2023","unstructured":"Chen B.; Lu X.; Zhou Q.; Chen Q.; Zhu S.; Li G.; Liu H.; PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer. PLoS One  2023,18(8),e0290031","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"Liu J.","year":"2018","unstructured":"Liu J.; Lichtenberg T.; Hoadley K.A.; Poisson L.M.; Lazar A.J.; Cherniack A.D.; Kovatich A.J.; Benz C.C.; Levine D.A.; Lee A.V.; Omberg L.; Wolf D.M.; Shriver C.D.; Thorsson V.; Hu H.; Caesar-Johnson S.J.; Demchok J.A.; Felau I.; Kasapi M.; Ferguson M.L.; Hutter C.M.; Sofia H.J.; Tarnuzzer R.; Wang Z.; Yang L.; Zenklusen J.C.; Zhang J.J.; Chudamani S.; Liu J.; Lolla L.; Naresh R.; Pihl T.; Sun Q.; Wan Y.; Wu Y.; Cho J.; DeFreitas T.; Frazer S.; Gehlenborg N.; Getz G.; Heiman D.I.; Kim J.; Lawrence M.S.; Lin P.; Meier S.; Noble M.S.; Saksena G.; Voet D.; Zhang H.; Bernard B.; Chambwe N.; Dhankani V.; Knijnenburg T.; Kramer R.; Leinonen K.; Liu Y.; Miller M.; Reynolds S.; Shmulevich I.; Thorsson V.; Zhang W.; Akbani R.; Broom B.M.; Hegde A.M.; Ju Z.; Kanchi R.S.; Korkut A.; Li J.; Liang H.; Ling S.; Liu W.; Lu Y.; Mills G.B.; Ng K-S.; Rao A.; Ryan M.; Wang J.; Weinstein J.N.; Zhang J.; Abeshouse A.; Armenia J.; Chakravarty D.; Chatila W.K.; de Bruijn I.; Gao J.; Gross B.E.; Heins Z.J.; Kundra R.; La K.; Ladanyi M.; Luna A.; Nissan M.G.; Ochoa A.; Phillips S.M.; Reznik E.; Sanchez-Vega F.; Sander C.; Schultz N.; Sheridan R.; Sumer S.O.; Sun Y.; Taylor B.S.; Wang J.; Zhang H.; Anur P.; Peto M.; Spellman P.; Benz C.; Stuart J.M.; Wong C.K.; Yau C.; Hayes D.N.; Parker J.S.; Wilkerson M.D.; Ally A.; Balasundaram M.; Bowlby R.; Brooks D.; Carlsen R.; Chuah E.; Dhalla N.; Holt R.; Jones S.J.M.; Kasaian K.; Lee D.; Ma Y.; Marra M.A.; Mayo M.; Moore R.A.; Mungall A.J.; Mungall K.; Robertson A.G.; Sadeghi S.; Schein J.E.; Sipahimalani P.; Tam A.; Thiessen N.; Tse K.; Wong T.; Berger A.C.; Beroukhim R.; Cherniack A.D.; Cibulskis C.; Gabriel S.B.; Gao G.F.; Ha G.; Meyerson M.; Schumacher S.E.; Shih J.; Kucherlapati M.H.; Kucherlapati R.S.; Baylin S.; Cope L.; Danilova L.; Bootwalla M.S.; Lai P.H.; Maglinte D.T.; Van Den Berg D.J.; Weisenberger D.J.; Auman J.T.; Balu S.; Bodenheimer T.; Fan C.; Hoadley K.A.; Hoyle A.P.; Jefferys S.R.; Jones C.D.; Meng S.; Mieczkowski P.A.; Mose L.E.; Perou A.H.; Perou C.M.; Roach J.; Shi Y.; Simons J.V.; Skelly T.; Soloway M.G.; Tan D.; Veluvolu U.; Fan H.; Hinoue T.; Laird P.W.; Shen H.; Zhou W.; Bellair M.; Chang K.; Covington K.; Creighton C.J.; Dinh H.; Doddapaneni H.V.; Donehower L.A.; Drummond J.; Gibbs R.A.; Glenn R.; Hale W.; Han Y.; Hu J.; Korchina V.; Lee S.; Lewis L.; Li W.; Liu X.; Morgan M.; Morton D.; Muzny D.; Santibanez J.; Sheth M.; Shinbro E.; Wang L.; Wang M.; Wheeler D.A.; Xi L.; Zhao F.; Hess J.; Appelbaum E.L.; Bailey M.; Cordes M.G.; Ding L.; Fronick C.C.; Fulton L.A.; Fulton R.S.; Kandoth C.; Mardis E.R.; McLellan M.D.; Miller C.A.; Schmidt H.K.; Wilson R.K.; Crain D.; Curley E.; Gardner J.; Lau K.; Mallery D.; Morris S.; Paulauskis J.; Penny R.; Shelton C.; Shelton T.; Sherman M.; Thompson E.; Yena P.; Bowen J.; Gastier-Foster J.M.; Gerken M.; Leraas K.M.; Lichtenberg T.M.; Ramirez N.C.; Wise L.; Zmuda E.; Corcoran N.; Costello T.; Hovens C.; Carvalho A.L.; de Carvalho A.C.; Fregnani J.H.; Longatto-Filho A.; Reis R.M.; Scapulatempo-Neto C.; Silveira H.C.S.; Vidal D.O.; Burnette A.; Eschbacher J.; Hermes B.; Noss A.; Singh R.; Anderson M.L.; Castro P.D.; Ittmann M.; Huntsman D.; Kohl B.; Le X.; Thorp R.; Andry C.; Duffy E.R.; Lyadov V.; Paklina O.; Setdikova G.; Shabunin A.; Tavobilov M.; McPherson C.; Warnick R.; Berkowitz R.; Cramer D.; Feltmate C.; Horowitz N.; Kibel A.; Muto M.; Raut C.P.; Malykh A.; Barnholtz-Sloan J.S.; Barrett W.; Devine K.; Fulop J.; Ostrom Q.T.; Shimmel K.; Wolinsky Y.; Sloan A.E.; De Rose A.; Giuliante F.; Goodman M.; Karlan B.Y.; Hagedorn C.H.; Eckman J.; Harr J.; Myers J.; Tucker K.; Zach L.A.; Deyarmin B.; Hu H.; Kvecher L.; Larson C.; Mural R.J.; Somiari S.; Vicha A.; Zelinka T.; Bennett J.; Iacocca M.; Rabeno B.; Swanson P.; Latour M.; Lacombe L.; T\u00eatu B.; Bergeron A.; McGraw M.; Staugaitis S.M.; Chabot J.; Hibshoosh H.; Sepulveda A.; Su T.; Wang T.; Potapova O.; Voronina O.; Desjardins L.; Mariani O.; Roman-Roman S.; Sastre X.; Stern M-H.; Cheng F.; Signoretti S.; Berchuck A.; Bigner D.; Lipp E.; Marks J.; McCall S.; McLendon R.; Secord A.; Sharp A.; Behera M.; Brat D.J.; Chen A.; Delman K.; Force S.; Khuri F.; Magliocca K.; Maithel S.; Olson J.J.; Owonikoko T.; Pickens A.; Ramalingam S.; Shin D.M.; Sica G.; Van Meir E.G.; Zhang H.; Eijckenboom W.; Gillis A.; Korpershoek E.; Looijenga L.; Oosterhuis W.; Stoop H.; van Kessel K.E.; Zwarthoff E.C.; Calatozzolo C.; Cuppini L.; Cuzzubbo S.; DiMeco F.; Finocchiaro G.; Mattei L.; Perin A.; Pollo B.; Chen C.; Houck J.; Lohavanichbutr P.; Hartmann A.; Stoehr C.; Stoehr R.; Taubert H.; Wach S.; Wullich B.; Kycler W.; Murawa D.; Wiznerowicz M.; Chung K.; Edenfield W.J.; Martin J.; Baudin E.; Bubley G.; Bueno R.; De Rienzo A.; Richards W.G.; Kalkanis S.; Mikkelsen T.; Noushmehr H.; Scarpace L.; Girard N.; Aymerich M.; Campo E.; Gin\u00e9 E.; Guillermo A.L.; Van Bang N.; Hanh P.T.; Phu B.D.; Tang Y.; Colman H.; Evason K.; Dottino P.R.; Martignetti J.A.; Gabra H.; Juhl H.; Akeredolu T.; Stepa S.; Hoon D.; Ahn K.; Kang K.J.; Beuschlein F.; Breggia A.; Birrer M.; Bell D.; Borad M.; Bryce A.H.; Castle E.; Chandan V.; Cheville J.; Copland J.A.; Farnell M.; Flotte T.; Giama N.; Ho T.; Kendrick M.; Kocher J-P.; Kopp K.; Moser C.; Nagorney D.; O\u2019Brien D.; O\u2019Neill B.P.; Patel T.; Petersen G.; Que F.; Rivera M.; Roberts L.; Smallridge R.; Smyrk T.; Stanton M.; Thompson R.H.; Torbenson M.; Yang J.D.; Zhang L.; Brimo F.; Ajani J.A.; Angulo Gonzalez A.M.; Behrens C.; Bondaruk J.; Broaddus R.; Czerniak B.; Esmaeli B.; Fujimoto J.; Gershenwald J.; Guo C.; Lazar A.J.; Logothetis C.; Meric-Bernstam F.; Moran C.; Ramondetta L.; Rice D.; Sood A.; Tamboli P.; Thompson T.; Troncoso P.; Tsao A.; Wistuba I.; Carter C.; Haydu L.; Hersey P.; Jakrot V.; Kakavand H.; Kefford R.; Lee K.; Long G.; Mann G.; Quinn M.; Saw R.; Scolyer R.; Shannon K.; Spillane A.; Stretch J.; Synott M.; Thompson J.; Wilmott J.; Al-Ahmadie H.; Chan T.A.; Ghossein R.; Gopalan A.; Levine D.A.; Reuter V.; Singer S.; Singh B.; Tien N.V.; Broudy T.; Mirsaidi C.; Nair P.; Drwiega P.; Miller J.; Smith J.; Zaren H.; Park J-W.; Hung N.P.; Kebebew E.; Linehan W.M.; Metwalli A.R.; Pacak K.; Pinto P.A.; Schiffman M.; Schmidt L.S.; Vocke C.D.; Wentzensen N.; Worrell R.; Yang H.; Moncrieff M.; Goparaju C.; Melamed J.; Pass H.; Botnariuc N.; Caraman I.; Cernat M.; Chemencedji I.; Clipca A.; Doruc S.; Gorincioi G.; Mura S.; Pirtac M.; Stancul I.; Tcaciuc D.; Albert M.; Alexopoulou I.; Arnaout A.; Bartlett J.; Engel J.; Gilbert S.; Parfitt J.; Sekhon H.; Thomas G.; Rassl D.M.; Rintoul R.C.; Bifulco C.; Tamakawa R.; Urba W.; Hayward N.; Timmers H.; Antenucci A.; Facciolo F.; Grazi G.; Marino M.; Merola R.; de Krijger R.; Gimenez-Roqueplo A-P.; Pich\u00e9 A.; Chevalier S.; McKercher G.; Birsoy K.; Barnett G.; Brewer C.; Farver C.; Naska T.; Pennell N.A.; Raymond D.; Schilero C.; Smolenski K.; Williams F.; Morrison C.; Borgia J.A.; Liptay M.J.; Pool M.; Seder C.W.; Junker K.; Omberg L.; Dinkin M.; Manikhas G.; Alvaro D.; Bragazzi M.C.; Cardinale V.; Carpino G.; Gaudio E.; Chesla D.; Cottingham S.; Dubina M.; Moiseenko F.; Dhanasekaran R.; Becker K-F.; Janssen K-P.; Slotta-Huspenina J.; Abdel-Rahman M.H.; Aziz D.; Bell S.; Cebulla C.M.; Davis A.; Duell R.; Elder J.B.; Hilty J.; Kumar B.; Lang J.; Lehman N.L.; Mandt R.; Nguyen P.; Pilarski R.; Rai K.; Schoenfield L.; Senecal K.; Wakely P.; Hansen P.; Lechan R.; Powers J.; Tischler A.; Grizzle W.E.; Sexton K.C.; Kastl A.; Henderson J.; Porten S.; Waldmann J.; Fassnacht M.; Asa S.L.; Schadendorf D.; Couce M.; Graefen M.; Huland H.; Sauter G.; Schlomm T.; Simon R.; Tennstedt P.; Olabode O.; Nelson M.; Bathe O.; Carroll P.R.; Chan J.M.; Disaia P.; Glenn P.; Kelley R.K.; Landen C.N.; Phillips J.; Prados M.; Simko J.; Smith-McCune K.; VandenBerg S.; Roggin K.; Fehrenbach A.; Kendler A.; Sifri S.; Steele R.; Jimeno A.; Carey F.; Forgie I.; Mannelli M.; Carney M.; Hernandez B.; Campos B.; Herold-Mende C.; Jungk C.; Unterberg A.; von Deimling A.; Bossler A.; Galbraith J.; Jacobus L.; Knudson M.; Knutson T.; Ma D.; Milhem M.; Sigmund R.; Godwin A.K.; Madan R.; Rosenthal H.G.; Adebamowo C.; Adebamowo S.N.; Boussioutas A.; Beer D.; Giordano T.; Mes-Masson A-M.; Saad F.; Bocklage T.; Landrum L.; Mannel R.; Moore K.; Moxley K.; Postier R.; Walker J.; Zuna R.; Feldman M.; Valdivieso F.; Dhir R.; Luketich J.; Mora Pinero E.M.; Quintero-Aguilo M.; Carlotti C.G.; Dos Santos J.S.; Kemp R.; Sankarankuty A.; Tirapelli D.; Catto J.; Agnew K.; Swisher E.; Creaney J.; Robinson B.; Shelley C.S.; Godwin E.M.; Kendall S.; Shipman C.; Bradford C.; Carey T.; Haddad A.; Moyer J.; Peterson L.; Prince M.; Rozek L.; Wolf G.; Bowman R.; Fong K.M.; Yang I.; Korst R.; Rathmell W.K.; Fantacone-Campbell J.L.; Hooke J.A.; Kovatich A.J.; Shriver C.D.; DiPersio J.; Drake B.; Govindan R.; Heath S.; Ley T.; Van Tine B.; Westervelt P.; Rubin M.A.; Lee J.I.; Aredes N.D.; Mariamidze A.; An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell  2018,173(2),400-416.e11","journal-title":"Cell"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1574892817666220831122226","volume":"18","author":"Guo R.","year":"2023","unstructured":"Guo R.; Dai H.; Liu F.; Liu M.; Li X.; Li T.; Liao J.; Chen Z.S.; Liu Y.; Fang S.; The prognostic and drug-targeting value of lymphoid enhancer-binding factor-1 in hepatocellular carcinoma. Rec Pat Anticancer Drug Discov  2023,18(2),211-223","journal-title":"Rec Pat Anticancer Drug Discov"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"13041","DOI":"10.18632\/aging.205218","volume":"15","author":"Cai H.","year":"2023","unstructured":"Cai H.; Chen S.; Wu Z.; Wang F.; Tang S.; Li D.; Wang D.; Guo W.; Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma. Aging (Albany NY)  2023,15(22),13041-13058","journal-title":"Aging (Albany NY)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2926218","DOI":"10.1155\/2023\/2926218","volume":"2023","author":"Zhou F.","year":"2023","unstructured":"Zhou F.; Lin Q.; Zheng Z.; Cytokine-like protein 1 (CYTL1) as a key target of M-stage immune infiltration in stomach adenocarcinoma. BioMed Res Int  2023,2023(1),2926218","journal-title":"BioMed Res Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"Love M.I.","year":"2014","unstructured":"Love M.I.; Huber W.; Anders S.; Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol  2014,15(12),550","journal-title":"Genome Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"675104","DOI":"10.3389\/fonc.2021.675104","volume":"11","author":"Ye X.","year":"2021","unstructured":"Ye X.; An L.; Wang X.; Zhang C.; Huang W.; Sun C.; Li R.; Ma H.; Wang H.; Gao M.; ALOX5AP predicts poor prognosis by enhancing M2 macrophages polarization and immunosuppression in serous ovarian cancer microenvironment. Front Oncol  2021,11,675104","journal-title":"Front Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"Yu G.","year":"2012","unstructured":"Yu G.; Wang L.G.; Han Y.; He Q.Y.; ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS  2012,16(5),284-287","journal-title":"OMICS"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"Subramanian A.","year":"2005","unstructured":"Subramanian A.; Tamayo P.; Mootha V.K.; Mukherjee S.; Ebert B.L.; Gillette M.A.; Paulovich A.; Pomeroy S.L.; Golub T.R.; Lander E.S.; Mesirov J.P.; Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA  2005,102(43),15545-15550","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8323487","volume":"2021","author":"Chen T.","year":"2021","unstructured":"Chen T.; Zhu C.; Wang X.; Pan Y.; LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Can J Gastroenterol Hepatol  2021,2021,1-12","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"H\u00e4nzelmann S.","year":"2013","unstructured":"H\u00e4nzelmann S.; Castelo R.; Guinney J.; GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics  2013,14(1),7","journal-title":"BMC Bioinformatics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"Bindea G.","year":"2013","unstructured":"Bindea G.; Mlecnik B.; Tosolini M.; Kirilovsky A.; Waldner M.; Obenauf A.C.; Angell H.; Fredriksen T.; Lafontaine L.; Berger A.; Bruneval P.; Fridman W.H.; Becker C.; Pag\u00e8s F.; Speicher M.R.; Trajanoski Z.; Galon J.; Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity  2013,39(4),782-795","journal-title":"Immunity"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"Yoshihara K.","year":"2013","unstructured":"Yoshihara K.; Shahmoradgoli M.; Mart\u00ednez E.; Vegesna R.; Kim H.; Torres-Garcia W.; Trevi\u00f1o V.; Shen H.; Laird P.W.; Levine D.A.; Carter S.L.; Getz G.; Stemke-Hale K.; Mills G.B.; Verhaak R.G.W.; Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun  2013,4(1),2612","journal-title":"Nat Commun"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e2300092","DOI":"10.1200\/PO.23.00092","volume":"7","author":"Quintanilha J.C.F.","year":"2023","unstructured":"Quintanilha J.C.F.; Storandt M.H.; Graf R.P.; Li G.; Keller R.; Lin D.I.; Ross J.S.; Huang R.S.P.; Schrock A.B.; Oxnard G.R.; Chakrabarti S.; Mahipal A.; Tumor mutational burden in real-world patients with pancreatic cancer: Genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol  2023,7(7),e2300092","journal-title":"JCO Precis Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e004485","DOI":"10.1136\/jitc-2021-004485","volume":"10","author":"Chakrabarti S.","year":"2022","unstructured":"Chakrabarti S.; Bucheit L.; Starr J.S.; Innis-Shelton R.; Shergill A.; Dada H.; Resta R.; Wagner S.; Fei N.; Kasi P.M.; Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer  2022,10(6),e004485","journal-title":"J Immunother Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.3390\/cancers14215344","volume":"14","author":"Zheng H.","year":"2022","unstructured":"Zheng H.; Long G.; Zheng Y.; Yang X.; Cai W.; He S.; Qin X.; Liao H.; Glycolysis-related SLC2A1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Cancers (Basel)  2022,14(21),5344","journal-title":"Cancers (Basel)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"PO.17.00073","DOI":"10.1200\/PO.17.00073","volume":"2017","author":"Bonneville R.","year":"2017","unstructured":"Bonneville R.; Krook M.A.; Kautto E.A.; Miya J.; Wing M.R.; Chen H.Z.; Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol  2017,2017,PO.17.00073","journal-title":"JCO Precis Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"816070","DOI":"10.3389\/fonc.2022.816070","volume":"12","author":"Zhong F.","year":"2022","unstructured":"Zhong F.; Liu J.; Gao C.; Chen T.; Li B.; Downstream regulatory network of MYBL2 mediating its oncogenic role in melanoma. Front Oncol  2022,12,816070","journal-title":"Front Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.7150\/jca.68673","volume":"13","author":"Wang Z.","year":"2022","unstructured":"Wang Z.; Wang K.; Yu X.; Chen M.; Du Y.; Comprehensive analysis of expression signature and immune microenvironment signature of biomarker Endothelin Receptor Type A in stomach adenocarcinoma. J Cancer  2022,13(7),2086-2104","journal-title":"J Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"11912","DOI":"10.3390\/ijms241511912","volume":"24","author":"Zheng D.","year":"2023","unstructured":"Zheng D.; Long S.; Xi M.; Identification of TRPM2 as a potential therapeutic target associated with immune infiltration: A comprehensive pan-cancer analysis and experimental verification in ovarian cancer. Int J Mol Sci  2023,24(15),11912","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"16244","DOI":"10.1038\/s41598-023-42171-5","volume":"13","author":"Chen B.","year":"2023","unstructured":"Chen B.; Ding X.; Wan A.; Qi X.; Lin X.; Wang H.; Mu W.; Wang G.; Zheng J.; Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer. Sci Rep  2023,13(1),16244","journal-title":"Sci Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1159\/000493625","volume":"49","author":"Rui X.","year":"2018","unstructured":"Rui X.; Xu Y.; Huang Y.; Ji L.; Jiang X.; lncRNA DLG1-AS1 promotes cell proliferation by competitively binding with miR-107 and up-regulating ZHX1 expression in cervical cancer. Cell Physiol Biochem  2018,49(5),1792-1803","journal-title":"Cell Physiol Biochem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1574891X16666210706153740","volume":"16","author":"Deng Y.","year":"2021","unstructured":"Deng Y.; Liu L.; Feng W.; Lin Z.; Ning Y.; Luo X.; High expression of MYL9 indicates poor clinical prognosis of epithelial ovarian cancer. Rec Pat Anticancer Drug Discov  2021,16(4),533-539","journal-title":"Rec Pat Anticancer Drug Discov"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1574892816666210211091543","volume":"16","author":"Liu L.","year":"2021","unstructured":"Liu L.; Hu K.; Zeng Z.; Xu C.; Lv J.; Lin Z.; Wen B.; Expression and clinical significance of microtubule-actin cross-linking factor 1 in serous ovarian cancer. Rec Pat Anticancer Drug Discov  2021,16(1),66-72","journal-title":"Rec Pat Anticancer Drug Discov"},{"key":"ref=50","first-page":"25","volume":"33","author":"Zhuang J.","year":"2014","unstructured":"Zhuang J.; Tu X.; Cao K.; Guo S.; Mao X.; Pan J.; The expression and role of tyrosine kinase ETK\/BMX in renal cell carcinoma. Journal of experimental and clinical cancer research. CR (East Lansing Mich)  2014,33(1),25","journal-title":"CR (East Lansing Mich)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.2147\/IJGM.S323591","volume":"14","author":"Lu X.","year":"2021","unstructured":"Lu X.; Li G.; Liu S.; Wang H.; Zhang Z.; Chen B.; Bioinformatics analysis of KIF1A expression and gene regulation network in ovarian carcinoma. Int J Gen Med  2021,14,3707-3717","journal-title":"Int J Gen Med"},{"key":"ref=52","first-page":"31","volume":"2022","author":"Kri\u010dkovi\u0107 E.","year":"2022","unstructured":"Kri\u010dkovi\u0107 E.; Novkovi\u0107 I.; Lukic T.; Kri\u010dkovi\u0107 Z.; Using DPSEEA framework to investigate the relation between arsenic concentration values in waters and cancer rates in AP vojvodina (North Serbia). Pol J Environ Stud  2022,2022,31","journal-title":"Pol J Environ Stud"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1186\/s12885-022-10128-y","volume":"22","author":"Zhu Y.","year":"2022","unstructured":"Zhu Y.; Zheng D.; Lei L.; Cai K.; Xie H.; Zheng J.; Yu C.; High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma. BMC Cancer  2022,22(1),1042","journal-title":"BMC Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e0245908","DOI":"10.1371\/journal.pone.0245908","volume":"16","author":"Xie J.","year":"2021","unstructured":"Xie J.; Peng Y.; Chen X.; Li Q.; Jian B.; Wen Z.; Liu S.; LACTB mRNA expression is increased in pancreatic adenocarcinoma and high expression indicates a poor prognosis. PLoS One  2021,16(1),e0245908","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"805311","DOI":"10.3389\/fimmu.2022.805311","volume":"13","author":"Kuang W.","year":"2022","unstructured":"Kuang W.; Wang X.; Ding J.; Li J.; Ji M.; Chen W.; Wang L.; Yang P.; PTPN2, a key predictor of prognosis for pancreatic adenocarcinoma, significantly regulates cell cycles, apoptosis, and metastasis. Front Immunol  2022,13,805311","journal-title":"Front Immunol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"864244","DOI":"10.3389\/fimmu.2022.864244","volume":"13","author":"You W.","year":"2022","unstructured":"You W.; Ke J.; Chen Y.; Cai Z.; Huang Z.; Hu P.; Wu X.; SQLE, A key enzyme in cholesterol metabolism, correlates with tumor immune infiltration and immunotherapy outcome of pancreatic adenocarcinoma. Front Immunol  2022,13,864244","journal-title":"Front Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"111502","DOI":"10.1016\/j.mce.2021.111502","volume":"539","author":"Pulawska K.","year":"2022","unstructured":"Pulawska K.; Ponikwicka-Tyszko D.; Lebiedzinska W.; Guo P.; Bernaczyk P.; Pilaszewicz-Puza A.; Li X.; Chrusciel M.; Lupu O.; Leskinen S.; Makela J.A.; Toppari J.; Wolczynski S.; Coelingh Bennink H.J.T.; Huhtaniemi I.; Rahman N.A.; Novel expression of zona pellucida 3 protein in normal testis; Potential functional implications. Mol Cell Endocrinol  2022,539,111502","journal-title":"Mol Cell Endocrinol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/ACI.0000000000000091","volume":"14","author":"Joly Y.","year":"2014","unstructured":"Joly Y.; Saulnier K.M.; Osien G.; Knoppers B.M.; The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol  2014,14(5),404-408","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref=59","first-page":"209","volume":"55","author":"Salari P.","year":"2017","unstructured":"Salari P.; Larijani B.; Ethical issues surrounding personalized medicine: A literature review. Acta Med Iran  2017,55(3),209-217","journal-title":"Acta Med Iran"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.theriogenology.2004.07.025","volume":"63","author":"Hinsch E.","year":"2005","unstructured":"Hinsch E.; Aires V.A.; Hedrich F.; Oehninger S.; Hinsch K.D.; A synthetic decapeptide from a conserved ZP3 protein domain induces the G protein-regulated acrosome reaction in bovine spermatozoa. Theriogenology  2005,63(6),1682-1694","journal-title":"Theriogenology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"9353","DOI":"10.3390\/ijms23169353","volume":"23","author":"Piergentili R.","year":"2022","unstructured":"Piergentili R.; Basile G.; Nocella C.; Carnevale R.; Marinelli E.; Patrone R.; Zaami S.; Using ncRNAs as tools in cancer diagnosis and treatment - The way towards personalized medicine to improve patients\u2019 health. Int J Mol Sci  2022,23(16),9353","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4149\/neo_2018_170115N36","volume":"65","author":"Koleckova M.","year":"2018","unstructured":"Koleckova M.; Janikova M.; Kolar Z.; MicroRNAs in triple-negative breast cancer. Neoplasma  2018,65(1),1-13","journal-title":"Neoplasma"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/healthcare9080965","volume":"9","author":"Cavaliere A.F.","year":"2021","unstructured":"Cavaliere A.F.; Perelli F.; Zaami S.; Piergentili R.; Mattei A.; Vizzielli G.; Scambia G.; Straface G.; Restaino S.; Signore F.; Towards personalized medicine: Non-coding RNAs and endometrial cancer. Healthcare (Basel)  2021,9(8),965","journal-title":"Healthcare (Basel)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-22-1125","volume":"28","author":"Dias Costa A.","year":"2022","unstructured":"Dias Costa A.; V\u00e4yrynen S.A.; Chawla A.; Zhang J.; V\u00e4yrynen J.P.; Lau M.C.; Williams H.L.; Yuan C.; Morales-Oyarvide V.; Elganainy D.; Singh H.; Cleary J.M.; Perez K.; Ng K.; Freed-Pastor W.; Mancias J.D.; Dougan S.K.; Wang J.; Rubinson D.A.; Dunne R.F.; Kozak M.M.; Brais L.; Reilly E.; Clancy T.; Linehan D.C.; Chang D.T.; Hezel A.F.; Koong A.C.; Aguirre A.J.; Wolpin B.M.; Nowak J.A.; Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer. Clin Cancer Res  2022,28(23),5167-5179","journal-title":"Clin Cancer Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/cancers11111627","volume":"11","author":"Thyagarajan A.","year":"2019","unstructured":"Thyagarajan A.; Alshehri M.S.A.; Miller K.L.R.; Sherwin C.M.; Travers J.B.; Sahu R.P.; Myeloid-derived suppressor cells and pancreatic cancer: Implications in novel therapeutic approaches. Cancers (Basel)  2019,11(11),1627","journal-title":"Cancers (Basel)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2018.08.009","volume":"155","author":"Mahajan U.M.","year":"2018","unstructured":"Mahajan U.M.; Langhoff E.; Goni E.; Costello E.; Greenhalf W.; Halloran C.; Ormanns S.; Kruger S.; Boeck S.; Ribback S.; Beyer G.; Dombroswki F.; Weiss F.U.; Neoptolemos J.P.; Werner J.; D\u2019Haese J.G.; Bazhin A.; Peterhansl J.; Pichlmeier S.; B\u00fcchler M.W.; Kleeff J.; Ganeh P.; Sendler M.; Palmer D.H.; Kohlmann T.; Rad R.; Regel I.; Lerch M.M.; Mayerle J.; Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma. Gastroenterology  2018,155(5),1625-1639.e2","journal-title":"Gastroenterology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"Farkona S.","year":"2016","unstructured":"Farkona S.; Diamandis E.P.; Blasutig I.M.; Cancer immunotherapy: The beginning of the end of cancer? BMC Med  2016,14(1),73","journal-title":"BMC Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/13543784.2021.1948532","volume":"31","author":"Rizzo A.","year":"2022","unstructured":"Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G.; Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs  2022,31(4),371-378","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.ctarc.2021.100328","volume":"27","author":"Rizzo A.","year":"2021","unstructured":"Rizzo A.; Brandi G.; Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun  2021,27,100328","journal-title":"Cancer Treat Res Commun"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","volume":"15","author":"Rizzo A.","year":"2021","unstructured":"Rizzo A.; Ricci A.D.; Brandi G.; Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol  2021,15(5),527-536","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/jclinpath-2017-204739","volume":"71","author":"Munro M.J.","year":"2018","unstructured":"Munro M.J.; Wickremesekera S.K.; Peng L.; Tan S.T.; Itinteang T.; Cancer stem cells in colorectal cancer: A review. J Clin Pathol  2018,71(2),110-116","journal-title":"J Clin Pathol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"554138","DOI":"10.3389\/fonc.2020.554138","volume":"10","author":"Wang L.","year":"2021","unstructured":"Wang L.; Liu W.; Liu J.; Wang Y.; Tai J.; Yin X.; Tan J.; Identification of immune-related therapeutically relevant biomarkers in breast cancer and breast cancer stem cells by transcriptome-wide analysis: A clinical prospective study. Front Oncol  2021,10,554138","journal-title":"Front Oncol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-publhealth-040617-014158","volume":"39","author":"Ramaswami R.","year":"2024","unstructured":"Ramaswami R.; Bayer R.; Galea S.; Precision medicine from a public health perspective. Annu Rev Public Health  2024,39(1),153-168","journal-title":"Annu Rev Public Health"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665350171241204153202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238196\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665350171241204153202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:26:26Z","timestamp":1745933186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238196\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298665350171241204153202","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}